Annual FCF
-$24.58 M
-$838.00 K-3.53%
July 31, 2024
Summary
- As of February 7, 2025, BCTX annual free cash flow is -$24.58 million, with the most recent change of -$838.00 thousand (-3.53%) on July 31, 2024.
- During the last 3 years, BCTX annual FCF has fallen by -$16.83 million (-217.19%).
Performance
BCTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$6.96 M
-$2.92 M-72.34%
October 31, 2024
Summary
- As of February 7, 2025, BCTX quarterly free cash flow is -$6.96 million, with the most recent change of -$2.92 million (-72.34%) on October 31, 2024.
- Over the past year, BCTX quarterly FCF has dropped by -$1.87 million (-36.81%).
- BCTX quarterly FCF is now -11615.07% below its all-time high of $60.40 thousand, reached on April 30, 2020.
Performance
BCTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$23.48 M
+$650.10 K+2.69%
October 31, 2024
Summary
- As of February 7, 2025, BCTX TTM free cash flow is -$23.48 million, with the most recent change of +$650.10 thousand (+2.69%) on October 31, 2024.
- Over the past year, BCTX TTM FCF has increased by +$7.53 million (+24.29%).
- BCTX TTM FCF is now -89502.67% below its all-time high of -$26.20 thousand, reached on October 31, 2006.
Performance
BCTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
BCTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.5% | -36.8% | +24.3% |
| 3 y3 years | -217.2% | -172.1% | -97.8% |
| 5 y5 years | -492.8% | -172.1% | -97.8% |
BCTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -217.2% | at low | -172.1% | +36.3% | -111.4% | +24.9% |
| 5 y | 5-year | -1841.9% | at low | <-9999.0% | +36.3% | -4403.3% | +24.9% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +36.3% | <-9999.0% | +24.9% |
BriaCell Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$6.96 M(+72.3%) | -$23.48 M(-2.7%) |
| Jul 2024 | -$24.58 M(+3.5%) | -$4.04 M(-20.6%) | -$24.13 M(-22.2%) |
| Apr 2024 | - | -$5.08 M(-31.3%) | -$31.01 M(-0.8%) |
| Jan 2024 | - | -$7.40 M(-2.7%) | -$31.26 M(+12.4%) |
| Oct 2023 | - | -$7.61 M(-30.3%) | -$27.81 M(+17.1%) |
| Jul 2023 | -$23.74 M(+90.2%) | -$10.92 M(+104.8%) | -$23.74 M(+47.0%) |
| Apr 2023 | - | -$5.33 M(+34.9%) | -$16.15 M(+3.2%) |
| Jan 2023 | - | -$3.95 M(+11.6%) | -$15.64 M(+9.8%) |
| Oct 2022 | - | -$3.54 M(+6.5%) | -$14.25 M(+14.1%) |
| Jul 2022 | -$12.48 M(+61.1%) | -$3.33 M(-31.1%) | -$12.48 M(+12.4%) |
| Apr 2022 | - | -$4.82 M(+88.7%) | -$11.10 M(-6.4%) |
| Jan 2022 | - | -$2.56 M(+43.7%) | -$11.87 M(+25.3%) |
| Oct 2021 | - | -$1.78 M(-8.6%) | -$9.47 M(+22.2%) |
| Jul 2021 | -$7.75 M(+512.2%) | -$1.95 M(-65.2%) | -$7.75 M(+25.0%) |
| Apr 2021 | - | -$5.59 M(+3432.2%) | -$6.20 M(+1019.4%) |
| Jan 2021 | - | -$158.20 K(+172.3%) | -$554.10 K(+6.3%) |
| Oct 2020 | - | -$58.10 K(-85.4%) | -$521.30 K(-58.8%) |
| Jul 2020 | -$1.27 M(-69.5%) | -$398.20 K(-759.3%) | -$1.27 M(-28.6%) |
| Apr 2020 | - | $60.40 K(-148.2%) | -$1.77 M(-49.4%) |
| Jan 2020 | - | -$125.40 K(-84.4%) | -$3.51 M(-9.0%) |
| Oct 2019 | - | -$802.70 K(-11.4%) | -$3.85 M(-7.1%) |
| Jul 2019 | -$4.15 M(+9.0%) | -$906.10 K(-45.8%) | -$4.15 M(-1.2%) |
| Apr 2019 | - | -$1.67 M(+254.1%) | -$4.20 M(+19.2%) |
| Jan 2019 | - | -$472.40 K(-56.9%) | -$3.52 M(-8.9%) |
| Oct 2018 | - | -$1.10 M(+14.4%) | -$3.87 M(+1.6%) |
| Jul 2018 | -$3.81 M(+147.9%) | -$958.00 K(-3.8%) | -$3.81 M(+25.2%) |
| Apr 2018 | - | -$996.10 K(+22.0%) | -$3.04 M(+10.3%) |
| Jan 2018 | - | -$816.70 K(-21.1%) | -$2.76 M(+22.7%) |
| Oct 2017 | - | -$1.03 M(+435.9%) | -$2.25 M(+46.4%) |
| Jul 2017 | -$1.54 M(+28.0%) | -$193.10 K(-72.9%) | -$1.54 M(-6.0%) |
| Apr 2017 | - | -$713.00 K(+132.3%) | -$1.63 M(+28.6%) |
| Jan 2017 | - | -$306.90 K(-4.8%) | -$1.27 M(+4.1%) |
| Oct 2016 | - | -$322.30 K(+10.8%) | -$1.22 M(+1.7%) |
| Jul 2016 | -$1.20 M(+28.0%) | -$290.90 K(-16.7%) | -$1.20 M(+6.8%) |
| Apr 2016 | - | -$349.40 K(+36.1%) | -$1.12 M(+4.3%) |
| Jan 2016 | - | -$256.80 K(-15.0%) | -$1.08 M(-12.7%) |
| Oct 2015 | - | -$302.00 K(+40.6%) | -$1.23 M(+31.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jul 2015 | -$937.00 K(+51.9%) | -$214.80 K(-29.2%) | -$937.00 K(+3.5%) |
| Apr 2015 | - | -$303.60 K(-26.5%) | -$905.20 K(+34.8%) |
| Jan 2015 | - | -$413.10 K(+7410.9%) | -$671.60 K(+73.7%) |
| Oct 2014 | - | -$5500.00(-97.0%) | -$386.60 K(-37.3%) |
| Jul 2014 | -$616.90 K(-32.0%) | -$183.00 K(+161.4%) | -$616.90 K(-5.3%) |
| Apr 2014 | - | -$70.00 K(-45.4%) | -$651.60 K(-3.5%) |
| Jan 2014 | - | -$128.10 K(-45.7%) | -$675.20 K(-1.4%) |
| Oct 2013 | - | -$235.80 K(+8.3%) | -$684.80 K(-24.5%) |
| Jul 2013 | -$907.30 K(-68.6%) | -$217.70 K(+132.6%) | -$907.30 K(-51.1%) |
| Apr 2013 | - | -$93.60 K(-32.0%) | -$1.86 M(-8.6%) |
| Jan 2013 | - | -$137.70 K(-70.0%) | -$2.03 M(-7.6%) |
| Oct 2012 | - | -$458.30 K(-60.7%) | -$2.20 M(-24.0%) |
| Jul 2012 | -$2.89 M(-8.2%) | -$1.17 M(+335.6%) | -$2.89 M(-20.0%) |
| Apr 2012 | - | -$267.90 K(-12.0%) | -$3.61 M(-15.9%) |
| Jan 2012 | - | -$304.60 K(-73.5%) | -$4.30 M(+2.5%) |
| Oct 2011 | - | -$1.15 M(-39.1%) | -$4.19 M(+33.1%) |
| Jul 2011 | -$3.15 M(+298.1%) | -$1.89 M(+99.1%) | -$3.15 M(+79.5%) |
| Apr 2011 | - | -$949.50 K(+376.7%) | -$1.75 M(+87.6%) |
| Jan 2011 | - | -$199.20 K(+80.8%) | -$935.10 K(+23.3%) |
| Oct 2010 | - | -$110.20 K(-77.8%) | -$758.40 K(-4.1%) |
| Jul 2010 | -$791.10 K(+167.2%) | -$495.50 K(+280.6%) | -$791.20 K(+70.4%) |
| Apr 2010 | - | -$130.20 K(+478.7%) | -$464.40 K(+29.2%) |
| Jan 2010 | - | -$22.50 K(-84.3%) | -$359.40 K(+0.4%) |
| Oct 2009 | - | -$143.00 K(-15.2%) | -$357.90 K(+20.9%) |
| Jul 2009 | -$296.10 K(+238.8%) | -$168.70 K(+569.4%) | -$296.00 K(+71.2%) |
| Apr 2009 | - | -$25.20 K(+20.0%) | -$172.90 K(0.0%) |
| Jan 2009 | - | -$21.00 K(-74.1%) | -$172.90 K(+6.8%) |
| Oct 2008 | - | -$81.10 K(+77.9%) | -$161.90 K(+85.0%) |
| Jul 2008 | -$87.40 K(-0.5%) | -$45.60 K(+81.0%) | -$87.50 K(+30.6%) |
| Apr 2008 | - | -$25.20 K(+152.0%) | -$67.00 K(+18.4%) |
| Jan 2008 | - | -$10.00 K(+49.3%) | -$56.60 K(-17.0%) |
| Oct 2007 | - | -$6700.00(-73.3%) | -$68.20 K(-22.2%) |
| Jul 2007 | -$87.80 K(<-9900.0%) | -$25.10 K(+69.6%) | -$87.70 K(+40.1%) |
| Apr 2007 | - | -$14.80 K(-31.5%) | -$62.60 K(+31.0%) |
| Jan 2007 | - | -$21.60 K(-17.6%) | -$47.80 K(+82.4%) |
| Oct 2006 | - | -$26.20 K | -$26.20 K |
| Jul 2006 | $0.00 | - | - |
FAQ
- What is BriaCell Therapeutics annual free cash flow?
- What is the all time high annual FCF for BriaCell Therapeutics?
- What is BriaCell Therapeutics annual FCF year-on-year change?
- What is BriaCell Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for BriaCell Therapeutics?
- What is BriaCell Therapeutics quarterly FCF year-on-year change?
- What is BriaCell Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for BriaCell Therapeutics?
- What is BriaCell Therapeutics TTM FCF year-on-year change?
What is BriaCell Therapeutics annual free cash flow?
The current annual FCF of BCTX is -$24.58 M
What is the all time high annual FCF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high annual free cash flow is $0.00
What is BriaCell Therapeutics annual FCF year-on-year change?
Over the past year, BCTX annual free cash flow has changed by -$838.00 K (-3.53%)
What is BriaCell Therapeutics quarterly free cash flow?
The current quarterly FCF of BCTX is -$6.96 M
What is the all time high quarterly FCF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high quarterly free cash flow is $60.40 K
What is BriaCell Therapeutics quarterly FCF year-on-year change?
Over the past year, BCTX quarterly free cash flow has changed by -$1.87 M (-36.81%)
What is BriaCell Therapeutics TTM free cash flow?
The current TTM FCF of BCTX is -$23.48 M
What is the all time high TTM FCF for BriaCell Therapeutics?
BriaCell Therapeutics all-time high TTM free cash flow is -$26.20 K
What is BriaCell Therapeutics TTM FCF year-on-year change?
Over the past year, BCTX TTM free cash flow has changed by +$7.53 M (+24.29%)